StockTake: Bioxyne’s deal to boost supply pipeline

Bioxyne (ASX:BXN) has secured a multi-million dollar deal, boosting its position as a leading manufacturer of alternative pharmaceuticals and cannabis-based products. 

The new deal is expected to generate $7 million in sales from NectarTek in financial year 2026, a 200 per cent increase on past orders.

Watch the video to hear more.

This video was developed in collaboration with Bioxyne, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.